Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Bionity.com
press clippingscannabinoids
Bionity.com: EXOZ awarded $2M NIH grant to advance cannabinoid analogues for drug discoveryJune 26, 2026
PRISM MarketView
press clippingscannabinoids
PRISM MarketView: NIH Cash Fuels eXoZymes’ Push Into Next‑Gen CannabinoidsJune 25, 2026
Ladder17 podcast: How eXoZymes is Scaling as a Public Company
nutraceuticalspress clippingspodcastperrimanNCT
Ladder17 podcast: How eXoZymes is Scaling as a Public CompanyJune 25, 2026
EXOZ gets $2 Million NIH Grant to Advance Cannabinoids for Drug Discovery
heltzenpress releaseinvestormedicinesciencecannabinoidskorman
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug DiscoveryJune 24, 2026
Scientist
jobs
ScientistJune 23, 2026
Process Development Engineer
jobs
Process Development EngineerJune 23, 2026
Webull Biotech Sector Webinar
investorperriman
CCO of eXoZymes, Perriman, to present at Webull's 'Biotech Sector' webinarJune 18, 2026
$6M fundraise closed
press releaseinvestor
eXoZymes Inc. Announces Closing of $6 Million Public OfferingJune 17, 2026
EXOZ announces pricing of public offering
press releaseinvestor
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and WarrantsJune 8, 2026
Rolling Stone: Next-gen cannabinoids - the innovative race to manufacture compounds
investormedicinepress clippingscannabinoids
Rolling Stone: Next-gen cannabinoids - the innovative race to manufacture compoundsMay 15, 2026
Previous page
Page 1 of 14
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark